ADARx Pharmaceuticals, Inc. (ADRX)

NASDAQ: ADRX · Real-Time Price · USD

17.68

+0.35 (1.99%)

At close: Oct 8, 2026, 4:00 PM EDT

17.41

-0.27 (-1.50%)

After-hours: Oct 8, 2026, 7:30 PM EDT

ADARx Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	6.13	3.45	-
Revenue Growth	-	-	-
Cost of Revenue	89.87	71.51	43.36
Gross Profit	-83.74	-68.06	-43.36
Selling, General & Admin	22.56	20.3	14.88
Operating Expenses	22.56	20.3	14.88
Operating Income	-106.3	-88.37	-58.23
Interest & Investment Income	16.66	13.64	11.4
Other Non Operating Income (Expenses)	1.78	1.64	0.48
Pretax Income	-87.87	-73.09	-46.36
Net Income	-87.87	-73.09	-46.36
Net Income to Common	-87.87	-73.09	-46.36
Net Income Growth	-	-	-
Shares Outstanding (Basic)	11	11	11
Shares Outstanding (Diluted)	11	11	11
Shares Change	-	3.34%	-
EPS (Basic)	-7.74	-6.43	-4.22
EPS (Diluted)	-7.74	-6.43	-4.22
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-90.21	259.35	-49.02
Free Cash Flow Per Share	-7.95	22.82	-4.46
Operating Margin	-1734.98%	-2562.05%	-
Profit Margin	-1434.14%	-2119.11%	-
Free Cash Flow Margin	-1472.37%	7519.66%	-
EBITDA	-105.12	-87.36	-57.5
D&A For EBITDA	1.18	1	0.73
EBIT	-106.3	-88.37	-58.23

SEC Filings: 10-K · 10-Q